"Targeting Hepatitis B Therapy to the Liver: Clinical Pharmacokinetic Considerations."

According to the authors' abstract of an article published in Clinical Pharmacokinetics, "The hepatitis B virus (HBV) is the world's most important chronic virus infection. The immunomodulator interferon-alpha (IFN alpha) is the only clinically applied drug available, despite its low response rate (approximately 30%) even in highly selected chronic carriers. Antiviral nucleoside analogues have proven to be potent inhibitors of viral replication in vitro, but their significant adverse effects which are, at least partially, due to their nonspecific body distribution, have forced the cessation of their clinical development in the past. For example, vidarabine causes severe neuromuscular...

Want to see the full article?

• Purchase this article for only $3.00